I believe you're wrong about efficacy trials for p
Post# of 15624
People on the I-H board who attended the Wall St. Conference spent most of their day with OWCP management, they were saying March 20th was when we'd hear about the trial, we did. Perhaps it was anticipated that more data would be provided, but their's a lot to do with the data once a trial ends, but the observation that results were excellent could be expressed from a quick look.
I cannot say that efficacy data that's been gathered to date is sufficient for drug approval in Israel or elsewhere, but believe it could be. The key is that it's sufficient to know it will be successful in treating people when made available in the U.S. or elsewhere, which appears to be the company's game plan.
Gary